{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:28:48Z","timestamp":1792877328693,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100008529","name":"Chiba University","doi-asserted-by":"publisher","award":["JP20jm0110015"],"award-info":[{"award-number":["JP20jm0110015"]}],"id":[{"id":"10.13039\/501100008529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of azole-resistant Aspergillus fumigatus (ARAF) among chronic pulmonary aspergillosis (CPA) patients treated with azoles in Japan is unknown. The aim of this study was to determine the detection rate of ARAF in isolates from CPA patients who were treated with azoles for varying durations. The potential mechanism of acquiring resistance was examined by sequencing cyp51A and hmg1, two genes associated with ARAF. A. fumigatus isolates (n\u00a0=\u00a0120) were collected from CPA patients (n\u00a0=\u00a0104) between February 2012 and February 2019, at National Hospital Organization Tokyo National Hospital. The isolates were tested for susceptibility to the azole drugs itraconazole (ITCZ) and voriconazole (VRCZ). The detection rate of ARAF among all isolates was 8.3% (n\u00a0=\u00a010). Of the 10 resistant isolates, eight were ITCZ-resistant and five were VRCZ-resistant. Among 47 isolates obtained from 36 CPA patients who were treated with ITCZ (for an average of 256 days) and\/or VRCZ (for an average of 29 days), the resistance rates were 17.0% and 10.6%, respectively. In addition, 46.2% of 13 isolates obtained from CPA patients with ongoing azole treatment at the time of antifungal therapy failure were resistant to azoles. Among the 10 ARAF isolates, a point mutation was detected in cyp51A in seven isolates and in hmg1 in two isolates. ARAF was detected at a high rate in CPA patients, particularly in those with ongoing long-term azole treatment, at the time of azole antifungal therapy failure.<\/jats:p>","DOI":"10.1093\/mmy\/myaa052","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T11:19:25Z","timestamp":1591355965000},"page":"327-334","source":"Crossref","is-referenced-by-count":37,"title":["High detection rate of azole-resistant<i>Aspergillus fumigatus<\/i>after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-5553","authenticated-orcid":false,"given":"Keita","family":"Takeda","sequence":"first","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"},{"name":"Department of Basic Mycobacteriology, Graduate School of Biomedical Science, Nagasaki University, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Medical Mycology Research Centre, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Medical Mycology Research Centre, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koiwa","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyota","family":"Shinfuku","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Narumoto","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fukami","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhisa","family":"Tamura","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Kamei","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Medical Mycology Research Centre, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2021040620583306100_bib1","doi-asserted-by":"crossref","first-page":"S104\u2013S109","DOI":"10.1093\/mmy\/myy070","article-title":"Chronic pulmonary aspergillosis update: a year in review","volume":"57","author":"Barac","year":"2019","journal-title":"Med Mycol"},{"key":"2021040620583306100_bib2","doi-asserted-by":"crossref","first-page":"1601062","DOI":"10.1183\/13993003.01062-2016","article-title":"Predictors of mortality in chronic pulmonary aspergillosis","volume":"49","author":"Lowes","year":"2017","journal-title":"Eur Respir J"},{"key":"2021040620583306100_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.resinv.2015.10.003","article-title":"Recent advances in chronic pulmonary aspergillosis","volume":"54","author":"Izumikawa","year":"2016","journal-title":"Respir Investig"},{"key":"2021040620583306100_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021040620583306100_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"2021040620583306100_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2021040620583306100_bib7","first-page":"581","article-title":"Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward","volume":"49","author":"Tashiro","year":"2011","journal-title":"Med Mycol"},{"key":"2021040620583306100_bib8","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J Infect Dis"},{"key":"2021040620583306100_bib9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021040620583306100_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2021040620583306100_bib11","doi-asserted-by":"crossref","first-page":"e31801","DOI":"10.1371\/journal.pone.0031801","article-title":"Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus","volume":"7","author":"Snelders","year":"2012","journal-title":"PLoS One"},{"key":"2021040620583306100_bib12","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med"},{"key":"2021040620583306100_bib13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2021040620583306100_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.05088-11","article-title":"Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature","volume":"56","author":"Camps","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol"},{"key":"2021040620583306100_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.48.2.568-574.2004","article-title":"Three-dimensional models of wild-type and mutated forms of cytochrome P450 14\u03b1-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding","volume":"48","author":"Xiao","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3201\/eid2410.180730","article-title":"Non-cyp51A azole-resistant Aspergillus fumigatus isolates with mutation in HMG-CoA reductase","volume":"24","author":"Hagiwara","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2021040620583306100_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","article-title":"Azole resistance in Aspergillus fumigatus: a growing public health concern","volume":"26","author":"Vermeulen","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2021040620583306100_bib19","doi-asserted-by":"crossref","first-page":"e1003633","DOI":"10.1371\/journal.ppat.1003633","article-title":"Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health","volume":"9","author":"Chowdhary","year":"2013","journal-title":"PLoS Pathog"},{"key":"2021040620583306100_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021040620583306100_bib21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/AAC.05394-11","article-title":"Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jiac.2014.01.003","article-title":"Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan","volume":"20","author":"Kikuchi","year":"2014","journal-title":"J Infect Chemother"},{"key":"2021040620583306100_bib23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jiac.2016.03.002","article-title":"Azole susceptibility in clinical and environmental isolates of Aspergillus fumigatus from eastern Hokkaido, Japan","volume":"22","author":"Toyotome","year":"2016","journal-title":"J Infect Chemother"},{"key":"2021040620583306100_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jiac.2019.09.002","article-title":"Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: a five-year single-center study in Japan","volume":"26","author":"Toyotome","year":"2020","journal-title":"J Infect Chemother"},{"key":"2021040620583306100_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/mmy\/myz003","article-title":"Prospective multicenter surveillance of clinically isolated Aspergillus species revealed azole-resistant Aspergillus fumigatus isolates with TR34\/L98H mutation in the Kyoto and Shiga regions of Japan","volume":"57","author":"Tsuchido","year":"2019","journal-title":"Med Mycol"},{"key":"2021040620583306100_bib26","first-page":"310","article-title":"Species identification, antifungal susceptibility, and clinical feature association of Aspergillus section nigri isolates from the lower respiratory tract","volume":"8","author":"Takeda","year":"2019","journal-title":"Med Mycol"},{"key":"2021040620583306100_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3314\/jjmm.48.37","article-title":"Molecular phylogenetics of multiple genes on Aspergillus section fumigati isolated from clinical specimens in Japan","volume":"48","author":"Yaguchi","year":"2007","journal-title":"Nihon Ishinkin Gakkai Zasshi"},{"key":"2021040620583306100_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jiac.2014.01.003","article-title":"Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan","volume":"20","author":"Kikuchi","year":"2014","journal-title":"J Infect Chemother"},{"key":"2021040620583306100_bib29","author":"Alexander","year":"2017","journal-title":"Reference Methods for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi"},{"key":"2021040620583306100_bib30","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi","author":"Alexander","year":"2017","edition":"1st edn"},{"key":"2021040620583306100_bib31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2021040620583306100_bib32","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/AAC.00514-12","article-title":"Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib33","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2021040620583306100_bib34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2021040620583306100_bib35","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.3109\/13693786.2010.508469","article-title":"Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection","volume":"49","author":"Howard","year":"2011","journal-title":"Med Mycol"},{"key":"2021040620583306100_bib36","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib37","doi-asserted-by":"crossref","first-page":"e01610","DOI":"10.1128\/AAC.01610-18","article-title":"Microsatellite typing and resistance mechanism analysis of voriconazole-resistant Aspergillus flavus isolates in South Korean hospitals","volume":"63","author":"Choi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib38","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/AAC.01189-10","article-title":"Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity","volume":"55","author":"Rajendran","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040620583306100_bib39","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1128\/AAC.42.7.1862","article-title":"Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsule in healthy volunteers","volume":"42","author":"Barone","year":"1998","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/4\/327\/36917900\/myaa052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/4\/327\/36917900\/myaa052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T20:05:15Z","timestamp":1666814715000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/59\/4\/327\/5869101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,7,9]]},"published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myaa052","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2020,7,9]]}}}